Procainamide absorption studies to test the feasibility of using a sustained-release preparation

Area of Science:

• Pharmacology
• Drug Delivery Systems

Background:

• Procainamide is a critical antiarrhythmic agent.
• Conventional formulations exhibit rapid drug release.
• Need for improved drug delivery systems for sustained therapeutic effects.

Purpose of the Study:

• To compare the in vitro release and in vivo pharmacokinetic profiles of a sustained-release procainamide formulation (Cardiorytmin Retard) against a conventional formulation (Pronestyl).
• To assess the feasibility of using sustained-release procainamide for improved dosing regimens.

Main Methods:

• In vitro drug release studies comparing Pronestyl and Cardiorytmin Retard.
• In vivo pharmacokinetic analysis of plasma procainamide concentrations after single doses in patients and healthy volunteers.
• Urinary recovery studies to assess drug bioavailability.

Main Results:

• Cardiorytmin Retard demonstrated prolonged drug release in vitro compared to Pronestyl.
• Peak plasma procainamide concentrations were lower and delayed with Cardiorytmin Retard.
• Slower decline in plasma concentrations and similar overall bioavailability were observed for Cardiorytmin Retard.
• Early urinary recovery was higher for Pronestyl, but overall recovery was comparable.

Conclusions:

• Sustained-release Cardiorytmin Retard exhibits slower absorption but comparable overall bioavailability to conventional Pronestyl.
• The sustained-release formulation is feasible for reducing dosing frequency without compromising therapeutic efficacy.